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Over the last decade, stem cell biology has undergone a
revolution in technological advances that will collectively have
major and long-lasting impact on regenerative medicine. These
include the ability to generate pluripotent stem cells from adult
bodycells and to grow mini-organs from these or from adult stem
cells in deﬁned culture conditions. Both approaches provide ways
to derive functional cells of human tissue that could be used for
transplantation and tissue repair. Laboratories worldwide now
produce cardiomyocytes, blood cells, insulin-producing B-cells,
liver, and even brain cells entirely routinely. A major advantage of
these approaches is that they enable the use of a patient’s own
body material to grow new cells and tissues, thereby preventing
life-long treatment with drugs to avoid rejection. The future of
stem cell biology and regenerative medicine looks extremely
bright. At the same time, however, we have witnessed a number
of incidents of dubious or even fraudulent clinical interventions
based on stem cells. The promise of stem cells and regenerative
medicine to beneﬁt patients is huge but has led to opportunistic
and disproportionate incentives to push results from basic science
into the clinic.
It is our ﬁrm conviction that acquiring knowledge and
developing technologies to use stem cells for clinical application
is best carried out in networks or virtual institutes in which
scientists from multiple disciplines collaborate, critically assess
each others’ results and create synergy by bringing together
knowledge and expertise from different subdisciplines. We have
participated for many years in multiple of these networks that
were funded by the European Commission or by the Dutch
Government, including EuroStemCell and EuroSystems (http://
www.eurostemcell.org), and the Netherlands Institute for Regen-
erative Medicine (http://www.nirmresearch.nl). In these networks,
the best scientists in the various subdisciplines of regenerative
medicine were united, training a new generation of young
researchers and medical doctors, and organizing courses and
summer schools to ensure interaction, communication of the
newest developments, and providing education in speciﬁc skills,
like managing intellectual property and entrepreneurship. In
addition, they organized public outreach activities. In spite of
positive evaluation by external advisory boards, these networks
are essentially one-time events, with no options for (competitive)
renewals. Thus, under the current regulations, collaborative
networks inevitably come to an end, no matter how successful
they have been.
The European Union (EU) and Dutch government have
prioritized regenerative medicine as an area of key strategic
relevance, but networks of stem cell biologists can only apply in
response to requests for applications, or ‘calls’. These call texts are
often very speciﬁc and limited in scope, and how they are deﬁned
is less than transparent for most researchers. In the current EU
research program, Horizon 2020, stem cell calls are all worded to
expedite clinical use. While no one in the ﬁeld denies the wide
clinical potential of stem cells, a single focus on clinical use
without a fundamental research base is bound to disappoint
public, patients, and politicians alike.
The Dutch government has embarked on a process to solicit
and then shortlist research questions originating from the public,
leading to the “Dutch National Research Agenda” (http://www.
wetenschapsagenda.nl/?lang=en). Regenerative Medicine is now
conﬁrmed as a publicly approved topic of national interest. What
is needed is a transparent funding scheme that will promote the
combination of insights from stem cell biologists, scientists
working on applied regenerative medicine, specialists in materials
science and others to develop a pipeline that will bring new
fundamental insights into the clinic in a sustainable way. The long-
term establishment of multi-disciplinary networks is the only
sound way to achieve this.
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